A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

NCT00931840 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: EZN-2208, Cetuximab and Irinotecan

Sponsor

Enzon Pharmaceuticals, Inc.